1. Resin (Polypropylene)
Not in registryaccess=api
Source Explicitly mentioned as impacting margins due to pass-through lags, particularly in Beauty. Partnership with PureCycle for recycled polypropylene.
Confidence: high
AptarGroup, Inc.
AptarGroup, Inc. provides dispensing, sealing, and material science solutions for beauty, personal care, home care, pharmaceutical, food, and beverage markets.
AptarGroup, Inc. provides dispensing, sealing, and material science solutions for beauty, personal care, home care, pharmaceutical, food, and beverage markets. Its Pharma segment, the largest contributor and generating over two-thirds of profits, offers critical drug delivery systems. Beauty and Closures segments supply pumps, valves, and specialized closures to a broad global customer base across these industries.
Not in registryaccess=api
Source Explicitly mentioned as impacting margins due to pass-through lags, particularly in Beauty. Partnership with PureCycle for recycled polypropylene.
Confidence: high
Not in registry
Source Crucial for Pharma's Injectables segment, especially for GLP-1, biologics, and vaccines.
Confidence: high
Not in registry
Source Mentioned as part of 'higher input costs' impacting margins, with pass-throughs contributing to sales growth.
Confidence: medium
Not in registry
Source General operational cost, implied by discussions around productivity initiatives and SG&A.
Confidence: medium
Not in registry
Source Implied by the diverse product portfolio (pumps, valves, closures) and general mentions of 'higher input costs.'
Confidence: medium
Not in registry
Source Implied by discussions of supply chain resilience and global operations.
Confidence: low
Not in registry
Metric/field Global Age-Standardized Obesity Prevalence Rate
Cadence annually
Why it matters Indicates the potential market size and long-term demand for GLP-1 drugs and related peptide therapies, a key growth driver for Aptar Pharma.
Signal to watch Accelerating rates signal expanding market opportunity (bullish).
Confidence: high
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field Global GLP-1 Drug Sales Growth (Year-over-Year)
Cadence quarterly
Why it matters Directly tracks market adoption and commercial success of GLP-1 drugs, indicating demand for peptide APIs and delivery systems supplied by Aptar Pharma.
Signal to watch Sustained double-digit growth is bullish, indicating strong demand for peptide APIs and delivery systems.
Confidence: high
Matchedfred · access=api · map_only
Metric/field RSFSXMV
Cadence monthly
Why it matters Reflects overall consumer spending trends in the US, impacting demand for Aptar's Beauty + Home and Food + Beverage segments.
Signal to watch Increasing retail sales indicate stronger consumer demand (bullish).
Confidence: high
Not in registryaccess=scrape
Metric/field Euro Area Industrial Production
Cadence monthly
Why it matters Measures manufacturing activity in the Euro Area, a significant market for Aptar's operations and customer base.
Signal to watch Rising industrial production suggests increased demand for Aptar's components from European customers (bullish).
Confidence: high
Not in registryaccess=scrape
Metric/field China Retail Sales Annual
Cadence monthly
Why it matters Indicates consumer spending strength in China, a key growth market for Aptar's Beauty and Closures segments.
Signal to watch Stronger retail sales growth in China signals robust demand for Aptar's products (bullish).
Confidence: high
Not in registry
Metric/field Number of active clinical trials for 'nasal drug delivery' OR 'pulmonary drug delivery' OR 'ophthalmic drug delivery' OR 'injectable drug delivery'
Cadence daily
Why it matters Aptar's Pharma segment is pipeline-driven; an increase in relevant clinical trials indicates future potential demand for its drug delivery systems.
Signal to watch Increasing number of active trials in key therapeutic areas is bullish.
Confidence: high
Not in registry
Metric/field New patent grants/applications by assignee 'AptarGroup, Inc.'
Cadence weekly
Why it matters Tracks Aptar's innovation pipeline and competitive positioning, especially for new technologies like inhaled/nasal GLP-1 therapies and fragrance refill systems.
Signal to watch Consistent new patent activity indicates ongoing innovation and market leadership (bullish).
Confidence: high
Not in registry
Metric/field Relative Search Volume for 'GLP-1 weight loss'
Cadence daily
Why it matters Directly measures consumer awareness and interest in GLP-1 therapies, indicating potential for organic demand that could translate to Aptar's injectable components.
Signal to watch Increasing search volume is bullish.
Confidence: medium
Not in registry
Metric/field Full-text search for 'Aptar' AND ('partnership' OR 'acquisition' OR 'collaboration')
Cadence event_driven
Why it matters Provides early alerts on strategic developments, such as new collaborations (e.g., Stevanato Group) or acquisitions (e.g., PULMOTREE), which impact Aptar's growth opportunities.
Signal to watch Announcements of new strategic partnerships or acquisitions are bullish.
Confidence: high
Not in registry
Metric/field Number of open job requisitions for 'Pharma' or 'R&D' roles
Cadence weekly
Why it matters Hiring trends, particularly in Pharma and R&D, can signal investment in growth areas and confidence in future pipeline development.
Signal to watch Increasing job postings in Pharma and R&D roles suggest strategic investment and growth (bullish).
Confidence: medium
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field Global GLP-1 Drug Sales Volume (Units) by Drug and Region
Cadence monthly
Why it matters Provides granular, direct data on market adoption and commercial success of GLP-1 drugs, indicating demand for peptide APIs and delivery systems supplied by Aptar Pharma.
Signal to watch Sustained growth in sales volume is bullish.
Confidence: high
Matchedglobaldata_healthcare_healthcare_forecasts_market_sizing · access=file · map_only
Metric/field Market size and growth rate for 'Injectable Drug Delivery Devices' and 'Nasal Drug Delivery Devices'
Cadence annually
Why it matters Provides forward-looking insights into the growth trajectory of key markets for Aptar Pharma, validating long-term strategic investments.
Signal to watch Upward revisions to market forecasts are bullish.
Confidence: high
Matchedconsumer_edge_pharmacy_claims_prescription_activity · access=file · map_only
Metric/field Prescription volume for GLP-1 therapies (by drug and manufacturer)
Cadence weekly
Why it matters Offers real-time insights into prescription trends for GLP-1 drugs, directly correlating to demand for Aptar's injectable components.
Signal to watch Consistent growth in prescription volumes is bullish.
Confidence: high
Matchedxeneta_ocean_freight_short_term_rates · access=file · map_only
Metric/field Ocean freight rates for key trade lanes (e.g., Asia-North America, Europe-North America)
Cadence daily
Why it matters Aptar operates globally and relies on efficient supply chains. Changes in freight costs directly impact its cost of goods sold and profitability.
Signal to watch Decreasing freight rates are bullish for margins.
Confidence: high
Matchedyole_group_supply_chain_company_market_share · access=file · map_only
Metric/field Market share and growth for 'Beauty Packaging Pumps' and 'Food & Beverage Dispensing Closures'
Cadence annually
Why it matters Provides competitive intelligence and market growth data for Aptar's Beauty and Closures segments, helping assess their performance relative to the broader market.
Signal to watch Aptar's market share gains or accelerating segment growth are bullish.
Confidence: high
AptarGroup (ATR) is positioned for sustained profitable growth, driven by its robust Pharma segment's strong demand in injectables (GLP-1, biologics) and divers
AptarGroup (ATR) is positioned for sustained profitable growth, driven by its robust Pharma segment's strong demand in injectables (GLP-1, biologics) and diverse drug delivery innovations. New CEO Gael Touya's focus on execution and disciplined capital allocation, alongside the abatement of emergency medicine headwinds, underpins long-term value. While North American Beauty profitability remains a key challenge requiring a multi-year transformation, the company's strong pipeline and strategic partnerships are compelling. (Updated: 2026-11-01)
Aptar's Pharma segment continues to demonstrate strong underlying growth, with core sales up 8% excluding emergency medicine in Q3 2026. This is driven by robust demand for injectable GLP-1 therapies, biologics, and vaccines, alongside significant growth in consumer healthcare and central nervous system therapies. The segment's broad-based strength and diverse portfolio mitigate reliance on any single product.
The Pharma pipeline is robust and maturing, with significant innovation across multiple delivery routes. New developments include Beat the Blink for ophthalmic dosing, a research collaboration for nose-to-brain delivery, the acquisition of PULMOTREE for pulmonary drug delivery, and Premia Precision for injectable components. These initiatives, coupled with strategic partnerships like Stevanato Group, position Aptar for long-term growth.
New CEO Gael Touya's clear priorities of profitable growth, execution, and disciplined capital allocation are expected to drive improved financial performance. The significant headwind from emergency medicine destocking is confirmed to be fully behind the company by Q4 2026, leading to anticipated year-over-year Pharma margin improvement and a strong finish to 2026.
Aptar continues to face persistent operational challenges and profitability issues, particularly within its Beauty segment in North America. Management acknowledges this is a 'major issue' that will require a non-linear, long-term transformation, not a 'quick fix,' indicating that significant improvements will take time to materialize.
While the emergency medicine destocking is concluding, the future growth rate for naloxone is expected to be a lower 'GDP plus' rate, reflecting market transitions from prescription to over-the-counter and generic versions. This suggests a reduced contribution from what was historically a high-margin growth driver.
The broader GLP-1 market presents risks from rapid capacity additions by pharmaceutical manufacturers and potential shifts towards oral GLP-1 formulations or less-frequent injectable dosing. Such changes could weaken demand for Aptar's injection devices and components, impacting utilization and pricing power despite the company's diversified portfolio.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Pharma Pipeline Advancement and Commercialization Milestones | The robust and maturing Pharma pipeline, with programs advancing through clinical development and towards commercialization across various delivery routes, is a key indicator of Aptar's long-term growth potential and innovation. | Announcements of new clinical study results (e.g., Beat the Blink), regulatory approvals (e.g., OTC switches, CE marks like LuerVax), new collaborations (e.g., Massachusetts General Hospital, Stevanato Group), and product launches (e.g., Premia Precision). | Positive clinical study outcomes, regulatory approvals, new strategic collaborations, and commercial launches of pipeline products = bullish. Delays, negative study results, or lack of new commercialization news = bearish. | Company press releases, SEC filings, and conference call transcripts, available on Aptar's investor relations website (investors.aptar.com). | 1. ClinicalTrials.gov — Clinical Study Results DatabaseNot in registry Metric/field Study Status and Results for Aptar-enabled drug delivery systems Cadence as available Why it matters Provides public information on the progress and outcomes of clinical trials utilizing Aptar's drug delivery technologies. Signal to watch Advancement to later phases or positive primary endpoint results (bullish) Confidence: Medium | [] |
| Beauty Segment Adjusted EBITDA Margin Improvement (North America Focus) | The North American Beauty segment's margin performance is a stated priority for the new CEO, and its improvement is critical for enhancing overall company profitability and validating management's execution capabilities. | Adjusted EBITDA margin for the Beauty segment, specifically focusing on North American operations. Management acknowledged it will not be a "quick fix" or "linear improvement" but has a plan for transformation. | Sequential improvement in Beauty's adjusted EBITDA margin in Q4 2026 and beyond, particularly with positive commentary on North America, indicates bullish progress. Continued stagnation or decline = bearish. | Company earnings reports and conference call transcripts, typically released quarterly on the investor relations section of Aptar's website (investors.aptar.com). The next update will be for Q4 2026 results, expected in early 2027. | [] | [] |
| Pharma Segment Core Sales Growth (excluding Emergency Medicine) | This metric indicates the underlying health and growth trajectory of Aptar's most profitable segment, especially given strong demand in GLP-1, biologics, and consumer healthcare, which are key growth drivers for the company. | Core sales growth rate for the Pharma segment, specifically excluding emergency medicine sales. Management reported 8% growth in Q3 2026 and expressed confidence in the 7-11% long-term corridor. | Core sales growth consistently at or above 8% (ex-emergency medicine) = bullish. Growth below 7% = bearish. | Company earnings reports and conference call transcripts, typically released quarterly on the investor relations section of Aptar's website (investors.aptar.com). The next update will be for Q4 2026 results, expected in early 2027. | [] | 1. IQVIA — Pharmaceutical Sales DataMatchediqvia_prescription_rx_data · access=file · map_only Metric/field Global GLP-1 Drug Sales Volume (Units) by Drug and Region Cadence monthly Why it matters Provides granular, direct data on market adoption and commercial success of GLP-1 drugs, indicating demand for peptide APIs and delivery systems. Signal to watch Sustained double-digit growth in GLP-1 sales volume (bullish) Confidence: High |
| Injectables Core Sales Growth (GLP-1, Biologics, Vaccines) | Injectables, driven by strong demand for GLP-1, biologics, and vaccines, is a high-growth sub-segment within Pharma, contributing significantly to the segment's overall performance and future growth potential. | Core sales growth rate for the Injectables sub-segment. Management reported 9% growth in Q3 2026 and noted strong pipeline activity across Annex 1, GLP-1, and biologics projects. | Sustained core sales growth at or above 9% in Injectables = bullish. Growth below high single-digits = bearish. | Company earnings reports and conference call transcripts, typically released quarterly on the investor relations section of Aptar's website (investors.aptar.com). The next update will be for Q4 2026 results, expected in early 2027. | [] | 1. IQVIA — Pharmaceutical Sales DataMatchediqvia_prescription_rx_data · access=file · map_only Metric/field Global GLP-1 Drug Sales Volume (Units) by Drug and Region Cadence monthly Why it matters Provides granular, direct data on market adoption and commercial success of GLP-1 drugs, indicating demand for peptide APIs and delivery systems. Signal to watch Sustained double-digit growth in GLP-1 sales volume (bullish) Confidence: High |
| Abatement of Emergency Medicine Sales Headwind | The anticipated decline in high-margin emergency medicine sales has been a significant headwind for Pharma's gross margins. Its abatement is crucial for improving overall profitability and removing a drag on growth. | Confirmation in Q4 2026 earnings that the approximately $65 million fiscal year 2026 decline in emergency medicine sales has fully abated, with no residual impact into 2027. | Emergency medicine sales decline tracking as expected in Q3 and fully abating by Q4 2026 = bullish. Larger than expected decline in Q3 or continued headwind into Q4/Q1 2027 = bearish. | Company earnings reports and conference call transcripts, typically released quarterly on the investor relations section of Aptar's website (investors.aptar.com). The next update will be for Q4 2026 results, expected in early 2027. | [] | [] |
Adjusted EPS is a direct measure of the company's profitability and its ability to meet its financial outlook, reflecting overall operational efficiency and mar
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Adjusted Earnings Per Share | $1.52 (-6% y/y) | Adjusted EPS is a direct measure of the company's profitability and its ability to meet its financial outlook, reflecting overall operational efficiency and market conditions. |
| Beauty Segment Adjusted EBITDA Margin | 11.4% (-70 bps y/y) | Improvement in this margin signals the successful resolution of operational issues and pricing lags, which is crucial for enhancing profitability in a segment that has historically lagged and is a focus for new leadership. |
| Pharma Core Sales Growth (excluding emergency medicine) | 8% y/y growth | This metric indicates the underlying health and growth trajectory of Aptar's most profitable segment, especially given strong demand in GLP-1 and biologics, which are key growth drivers for the company. |
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Beauty Segment Adjusted EBITDA Margin | declined 13.5% | Improvement in this margin signals the successful resolution of operational issues and pricing lags, which is crucial for enhancing profitability in a segment that has historically lagged and is a focus for new leadership. | A margin of 13.5% or higher, representing a significant sequential improvement from Q2 2026's 12.2%, indicating successful resolution of resin pass-through lags and progress on operational challenges. | Improvement in Beauty's margin confirms new leadership's ability to address operational issues and enhance profitability in a historically lagging segment. This validates the thesis of progressive operational improvements beyond Pharma, driving overall value creation. | 11.4% (-70 bps y/y) | No | Beauty's adjusted EBITDA margin was 11.4% in Q3 2026, a decline of 70 basis points year-over-year and a sequential decline from Q2 2026's 12.2%. Management acknowledged that North American operations' margin performance is not where it needs to be and that improvement will not be a 'quick fix' or 'linear progression'. | |
| Adjusted Earnings Per Share | declined 15% | Adjusted EPS is a direct measure of the company's profitability and its ability to meet its financial outlook, reflecting overall operational efficiency and market conditions. The company provided specific guidance for Q3. | Adjusted EPS of $1.55 or higher, exceeding both analyst consensus ($1.47) and the high end of company guidance ($1.53), signaling strong overall operational efficiency and profitability. | Beating EPS guidance and consensus demonstrates robust financial performance and effective management across segments. This reinforces confidence in Aptar's ability to translate strategic initiatives into bottom-line growth, supporting a higher valuation. | $1.52 (-6% y/y) | No | Adjusted EPS was $1.52, a decrease of 6% compared to the prior year. This was at the higher end of the company's guidance range for the quarter, but it did not meet the rerating trigger of $1.55 or higher. | |
| Pharma Core Sales Growth (excluding emergency medicine) | 8% | This metric indicates the underlying health and growth trajectory of Aptar's most profitable segment, especially given the strong demand in GLP-1 and biologics, which are key growth drivers for the company. | Core sales growth of 9% or higher, demonstrating continued acceleration and strong demand in key areas like GLP-1 therapies and biologics, surpassing the 8% growth seen in Q2 2026. | Sustained high single-digit or double-digit growth in Pharma, especially excluding emergency medicine, is critical. It validates the primary growth driver of the investment thesis, showcasing strong market penetration and innovation in high-value drug delivery systems. | 8% y/y growth | No | Pharma core sales, excluding the impact of the anticipated emergency medicine headwind, grew 8% in the quarter. While this demonstrated underlying strength and was consistent with the prior quarter, it did not meet the rerating trigger of 9% or higher. Management expressed confidence in the 7-11% long-term growth corridor for Pharma. | |
Can Aptar's Pharma segment sustain its underlying 8% core sales growth (excluding emergency medicine) and effectively translate its robust and maturing pipeline
Can Aptar's Pharma segment sustain its underlying 8% core sales growth (excluding emergency medicine) and effectively translate its robust and maturing pipeline, including new ophthalmic biologics and nasal delivery initiatives, into accelerated commercialization and sustained long-term growth?
Will the new CEO's "transformation" plan for North American Beauty operations show initial signs of sequential adjusted EBITDA margin improvement in Q4 2026, or will profitability challenges persist, impacting overall segment performance?
With the emergency medicine sales headwind expected to be fully behind Aptar by Q4 2026, will the company achieve its Q4 adjusted EPS guidance of $1.39 to $1.47, driven by improved Pharma margins and underlying strength in other segments?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Profitable Growth, Execution, and Disciplined Capital Allocation**: Gael Touya, in his first earnings call as CEO, explicitly stated these as his straightforward priorities across Aptar. 2. **Improving North American Beauty Profitability**: Management acknowledged that the margin performance in North America Beauty is not where it needs to be, despite strong top-line growth. Gael emphasized a deep dive into diagnostics, understanding issues, and having a plan for transformation, focusing on execution, discipline, and accountability. 3. **Deepening Pharma Differentiation and Pipeline Conversion**: Management highlighted the underlying strength of the Pharma business, driven by broad-based demand and innovation. They aim to extend leadership, become the partner of choice, and provide more visibility into the robust and maturing pipeline across various delivery routes (ophthalmic, nasal, inhalation, injectables). | Call Takeaway & ToneThe call conveyed a cautiously optimistic and determined tone. Aptar delivered solid Q3 2026 results, with core sales growth across all segments and adjusted EPS at the high end of guidance. The Pharma segment showed strong underlying performance, and the significant headwind from emergency medicine destocking is expected to conclude by Q4 2026. New CEO Gael Touya outlined clear priorities for profitable growth, execution, and disciplined capital allocation, with a strong focus on addressing the persistent profitability challenges in North American Beauty, acknowledging that this transformation will require time and sustained effort. The robust and maturing Pharma pipeline was highlighted as a key driver for future long-term growth. | Prior Quarter'S Y/Y Growth By SegmentPharma core sales increased 1% (excluding emergency medicine, core sales increased 8%); Beauty core sales increased 1%; Closures core sales increased 4%. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Pharma Margin Dynamics and Emergency Medicine Destocking**: Analysts questioned the Q3 Pharma margin trend and the status of the emergency medicine destock. Management responded that Pharma's adjusted EBITDA margin of 36.4% was strong, driven by broad-based revenue, royalties, and productivity initiatives, despite being slightly down year-over-year from an abnormally high prior year. They confirmed the $65 million emergency medicine destocking impact was on track to be fully behind them by Q4 2026, with no residual impact into 2027, though future naloxone growth would be a lower 'GDP plus' rate. 2. **North American Beauty Profitability and Strategic Changes**: Analysts pressed on what new CEO Gael Touya would do differently to address the long-standing profitability issues in North American Beauty. Gael acknowledged the 'major issue' and 'frustration,' stating they had a diagnostic and a plan for transformation, focusing on improving competition (scaling up in growing markets like indie brands, regaining market share) and execution (operational excellence, quality, agile supply chain). He cautioned that it would not be a 'quick fix' or 'linear improvement.' 3. **Pharma Long-Term Growth Trajectory and Pipeline Contribution**: Analysts inquired if Pharma's long-term growth target of 7-11% could be exceeded, given strong intranasal drug growth and recent performance. Management expressed confidence in the 7-11% corridor as a long-term trajectory, emphasizing the robustness and maturing nature of their pipeline across diverse therapeutic areas (ophthalmic, nasal, inhalation, injectables), and the consistent contribution from repeat business and pipeline conversion. | Revenue SegmentsPharma core sales increased 1% (excluding emergency medicine, core sales grew 8%); Beauty core sales increased 8%; Closures core sales increased 11%. |
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Pharma Segment Growth and Innovation**: Management emphasized the strong performance and pipeline in the pharma segment, driven by injectables (GLP-1, biologics, vaccines), consumer healthcare, and prescription businesses. They highlighted strategic investments in formulation development, analytical services, regulatory support, and patient engagement, including patent applications for inhaled/nasal GLP-1 therapies and the Ensorb technology for nitrosamine reduction. 2. **Operational Improvements and Profitability**: Management acknowledged ongoing operational challenges in the Beauty and Closures segments but noted progressive improvements since the first quarter. They are focused on enhancing operational performance, particularly addressing the bottom-line issues in Beauty, and effectively managing higher input costs through customer pass-throughs. 3. **Smooth CEO Transition and Future Strategic Direction**: The call marked the final earnings call for outgoing CEO Stephan Tanda and the introduction of incoming CEO Gael Touya. Both leaders expressed confidence in the company's future, with Gael outlining his priorities to drive profitable growth, ensure consistent execution, and thoughtfully allocate capital. | Call Takeaway & ToneThe call presented a mixed but cautiously optimistic tone. Management reported solid second-quarter performance with positive sales growth across all three segments and adjusted EPS exceeding guidance, primarily driven by strong results in the Pharma segment. A significant focus was placed on the strategic importance of the pharma portfolio, particularly in high-growth areas like GLP-1 therapies and biologics, and ongoing efforts to enhance operational efficiency in Beauty and Closures. The smooth CEO transition from Stephan Tanda to Gael Touya was a central theme, with both leaders expressing confidence in Aptar's foundational strengths and future growth prospects. While acknowledging persistent challenges in the Beauty segment and the anticipated impact of emergency medicine destocking, management conveyed a clear strategy for addressing these issues and a strong belief in the company's long-term value creation. | Prior Quarter'S Y/Y Growth By SegmentPharma core sales decreased 1%. Beauty core sales increased 3%. Closures core sales were flat. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Beauty Segment's Sustained Growth and Structural Actions**: Analysts questioned when the Beauty segment would achieve sustained growth in volume and earnings, and if more structural actions would be taken to improve its performance, especially in the Americas. Management acknowledged the shortfall in the Americas and stated they have clear ideas to address it, but it was "too early to commit to that," with Gael Touya emphasizing an "open-minded approach" and focusing on the best interests of customers and shareholders. 2. **Gross Margin Expansion and Pharma's Underlying Growth Momentum**: Analysts inquired about expectations for gross margin expansion in the second half of the year and whether Pharma's strong 8% underlying growth momentum would continue. Management confirmed expectations for gross margin improvement in the second half as the emergency medicine headwind abates and operational improvements in Beauty and Closures progress. For Pharma, they expressed confidence in achieving long-term growth targets (7-11% core sales growth) due to a robust pipeline and strong market positions. 3. **Emergency Medicine Impact and Resin Pass-Throughs**: Analysts sought clarification on the dollar impact of emergency medicine sales in Q2 and the contribution of resin pass-throughs to core sales. Management reiterated that the emergency medicine impact was in line with expectations, with the majority of the year-over-year headwind incurred in the first half and expected to abate by Q4. They confirmed successful resin pass-throughs across all segments, noting a timing lag in Beauty that negatively impacted its margin by approximately 80-90 basis points, which is expected to be resolved in Q3. | Revenue SegmentsPharma core sales increased 1% (excluding emergency medicine, core sales increased 8%). Beauty core sales increased 1%. Closures core sales increased 4%. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAptar is expanding its ophthalmic opportunities with the introduction of Beat the Blink, a technology designed to improve dosing precision and patient experience, being developed through an exclusive collaboration with Bausch + Lomb. Early clinical studies of Beat the Blink have shown strong patient acceptance and preference. The company is also seeing biologics in clinical testing for ophthalmic areas like limbal stem cell deficiency, macular degeneration, and dry eye disease, indicating meaningful long-term growth potential beyond injectables. Aptar is supporting the transition of an acne treatment from prescription to over-the-counter in the U.S., reflecting the growing intersection of pharmaceutical innovation and consumer skin care. In nasal drug delivery, a research collaboration with Massachusetts General Hospital aims to advance nose-to-brain delivery science for neurological and central nervous system diseases. The pipeline for nasally delivered therapies includes Phase III programs in pain management and severe allergic reactions, Phase II programs for ALS and other neurological diseases, and earlier-stage opportunities across schizophrenia, nausea, concussion, Alzheimer's, dementia, and migraine. The LuerVax intranasal delivery system and Spray Divider have received the European conformity mark, enhancing support for intranasal vaccine development. In inhalation, a collaboration with Macquarie University focuses on high-dose dry powder delivery of biologics using Aptar's orbital inhaler platform, and the acquisition of PULMOTREE adds Kolibri non-propellant liquid inhaler technology. Aptar also launched Premia Precision, a new quality standard for elastomeric components for complex injectable therapies, including biologics and GLP-1 medicines. A collaboration with Stevanato Group aims to advance system-level solutions for injectable drug development. In Beauty, recent wins include a patented fragrance refill technology with Bvlgari's Le Gemme Tygar Travel Spray, a premium cosmetic pump for Helena Rubinstein's Powercell Serum, and a custom pump for SK-II Facial Treatment Serum. For Closures, the SimpliSqueeze valve technology is being used for Hormel Foods' Wholly Guacamole and IP One's Dance Body Wash, and a partnership with McCormick led to a 2-color easy open closure for spices. | About CompetitionAptar aims to become the partner of choice for its customers through its technology, scientific expertise, services, and regulatory capabilities. The company believes it has the best product portfolio on the market and can support customers through formulation development, analytical testing, and regulatory capabilities to ensure first-time approval. Aptar's growth opportunities in Pharma are not dependent on one product or one therapeutic category, reflecting the depth of its portfolio and innovation pipeline. The company is not predicated on any single blockbuster drug to meet its long-term targets, preferring to hit singles or doubles rather than relying on home runs. Aptar focuses on areas where it has a differentiated position and the 'right to win'. | About The Broader IndustryThe pharmaceutical industry is seeing biologics being disseminated through routes of delivery beyond injectables, including ophthalmic and pulmonary applications. There is a growing intersection of pharmaceutical innovation and consumer skin care, as evidenced by prescription-to-OTC switches for treatments like acne. Nose-to-brain delivery is an emerging pathway for therapies targeting neurological and central nervous system diseases. The respiratory health market is transitioning to next-generation lower carbon metered dose inhalers, with one program using Aptar's valve technology progressing to regulatory review in Europe. The market for naloxone, an emergency medicine, is transitioning from prescription to over-the-counter and generic versions, a rapid shift not typically seen in pharma life cycle management. Federal funding continues to support naloxone purchasing and distribution, as well as substance use prevention, treatment, and recovery programs. EvaluatePharma projects a 14% growth rate in the top 10 intranasal drugs. The beauty market continues to see strong demand for prestige fragrance and color cosmetics, with indie beauty brands performing well. Regulatory compliance, particularly with Annex 1, is raising the bar for pharmaceutical players. | Where Things Are HeadedAptar expects to finish 2026 on a strong note, driven by its Pharma segment, which anticipates continued growth across consumer health care dispensing systems and elastomeric components for injectables. The emergency medicine destocking headwind is expected to be behind the company in the fourth quarter of 2026. Pharma margins are projected to improve year-over-year in Q4 due to productivity initiatives and operational efficiencies. Gael Touya, the new CEO, outlined his priorities as profitable growth, execution, and disciplined capital allocation. The Pharma pipeline is maturing, with programs advancing through clinical development and moving closer to potential approval and commercialization. The naloxone market is expected to see GDP, GDP plus type growth moving forward, with better visibility by Q1 2027. In Beauty, the focus is on driving growth with differentiated premium solutions, while acknowledging that improving North American operations will be a transformation that takes time and will not be a linear progression. Closures are expected to continue momentum from innovation and positive customer adoption in beverage applications. Aptar is confident in its long-term Pharma core sales growth target of 7% to 11%. The company anticipates Q4 adjusted earnings per share to be in the range of $1.39 to $1.47, reflecting approximately 17% growth from prior year Q4 at comparable exchange rates. Full-year 2026 capital investments are expected to be $260 million to $280 million, and depreciation and amortization expense between $310 million and $320 million. Virginie Maes has been appointed President of Aptar Pharma, effective January 1, to deepen customer partnerships and pursue growth opportunities. | Updates On ThemePeptide | Bullish-Leaning Quotes (Short)Our results in the quarter demonstrate the underlying strength of our businesses with 5% core sales growth across all 3 segments and adjusted earnings per share at the higher end of our guidance range. Our Pharma growth opportunities are not dependent on one product or one therapeutic category. We expect Aptar to finish on a strong note, driven by Pharma. Pharma is a phenomenal business. I'm confident with that long-term target [7%-11% Pharma growth]. | Bearish-Leaning Quotes (Short)The margin performance, mostly in North America is not where it needs to be. Sales growth alone is not our objective. That's not going to be a quick fix. That's not going to be a linear improvement. I'm not satisfied with the performance of North America. | HiringAptar announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, who brings deep global pharma and medical experience and a strong customer and growth orientation. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAptar is expanding its value proposition beyond core delivery systems to include formulation development, analytical services, regulatory support, and patient engagement. The company has patent applications related to inhaled and nasal GLP-1 therapies, exploring future growth opportunities in biologics and high-value therapeutic areas. Aptar's Ensorb technology, a first-of-its-kind packaging solution, addresses nitrosamine impurities in pharmaceutical products, offering a new tool for risk reduction and regulatory compliance. A collaborative system framework for injectable therapies is being implemented to provide customers with earlier insights into assembled system performance, aiding development decisions and risk management. The approval of Chiesi's PMDI utilizing HFA-152a in the UK, a next-generation propellant with low global warming potential, is expected to expand patient access to essential respiratory therapies. Nasal delivery is seeing growing interest across a wider range of therapeutic areas, including central nervous system disorders, beyond traditional allergy and migraine applications. The FDA's updated guidance for generic inhaled therapies, which removes certain clinical study and bioequivalence testing requirements, is seen as a positive development to bring more generic inhaled products to market more efficiently. In beauty, Aptar launched its autoloading dosing dropper technology for Dermalogica's Pro-Collagen Banking booster skincare product, addressing consumer needs for dosage control and convenience. For closures, new launches include a tabletop closure for Heinz's dipping sauces in North America and a Simply Squeeze valve for easy, one-handed hydration in China. | About CompetitionAptar focuses on premiumization, differentiated consumer experiences, and dispensing technologies to help customers stand out in increasingly competitive beauty categories. The company views protecting its intellectual property, technical expertise, and manufacturing know-how as crucial differentiators in the marketplace. Aptar aims to strengthen its capabilities to maintain its position as a leading company in its respective markets. | About The Broader IndustryA recent survey indicates that 11% of Americans are currently taking GLP-1 for weight loss, a significant increase from 3% in 2024, highlighting a growing market trend. The FDA has issued guidance on nitrosamine impurities in pharmaceutical products, impacting manufacturers' regulatory compliance and recall recommendations. There is growing interest in nasal delivery for a widening range of therapeutic areas, including central nervous system disorders, where rapid onset and direct access to the CNS offer therapeutic advantages. The FDA's update to product-specific guidance for generic inhaled therapies, by removing certain requirements, is expected to streamline the market entry for generic PMDI products. The beauty market is seeing continued growth of indie brands, which are capturing consumer interest. The industry has experienced higher input costs due to the recent conflict in the Middle East, which Aptar has largely offset through customer pass-throughs. The respiratory health market is transitioning to new propellants, with Aptar positioned to support this change. Biologics currently account for over 50% of pharmaceutical research and development globally. Regulatory compliance, particularly with Annex 1, is raising the bar for pharmaceutical players. | Where Things Are HeadedAptar is confident in its future success and expects to deliver profitable growth and long-term value for shareholders under new leadership. The company plans to continue exploring capabilities for future growth opportunities in biologics and other high-value therapeutic areas. Aptar's strategy involves advancing its role in the pharmaceutical development process, from drug formulation to patient engagement. Management anticipates that the year-over-year headwind from emergency medicine sales will abate by the fourth quarter of 2026. Gross margins are expected to improve in the second half of the year as the emergency medicine dynamic eases and operational improvements in beauty and closures continue. Aptar expects growth across all three segments, driven by strong demand in pharma (excluding emergency medicine), continued momentum in closures, and improving trends in beauty. The incoming CEO, Gael Touya, outlined his priorities: driving profitable growth, consistent execution, and thoughtful capital allocation. The company is confident in its outlook for the third quarter and its long-term prospects based on current demand trends and second-quarter momentum. | Updates On ThemePeptide | Bullish-Leaning Quotes (Short)“Aptar is well positioned for continued success.” | Bearish-Leaning Quotes (Short)“We have fallen short in The Americas for different reasons. We have fallen short in North America and still wrestling with operational issues and now came this Brazil situation.” |
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-10-29 | Aptar reported solid Q3 2026 results, with 5% core sales growth and adjusted EPS at the high end of guidance. Pharma's underlying business grew 8% (excluding emergency medicine), which is expected to fully abate in Q4. New CEO Gael Touya prioritized profitable growth, acknowledging North American Beauty's "major issue" requiring a long-term fix. The stock's 5.02% gain, significantly outperforming SPY, indicates strong market confidence in Pharma's strength and the ending of key headwinds. | Earnings Transcript | Positive | +5.02% (vs SPY: +6.67%) |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ATR_4d891b21 | effective January 1 | 2027-01-01 | 2027-01-01 | Virginie Maes assumes the role of President of Aptar Pharma. | Her leadership is expected to build on strong foundations, deepen customer partnerships, and pursue significant growth opportunities across the Pharma portfolio. | Ticker | 2026-10-29 | earnings_transcript |
| ATR_ee4013b0 | by Q1 2027 | 2027-01-01 | 2027-03-31 | AptarGroup expects to gain better visibility on the baseline growth rate for the naloxone market. | This will provide clarity on the future revenue and margin trajectory for a previously high-growth, high-margin product, influencing Pharma segment expectations. | Ticker | 2026-10-29 | earnings_transcript |